A comprehensive view of AGC Biologics. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Health Care Sector Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

Essential Pharma partners with AGC Biologics for late-phase clinical manufacturing of Hu14.18; Hu14.18 shows positive patient outcomes in Phase II trial with 3-year event-free survival of 73.7% and overall survival of 86.0%.

AGC Biologics Appointments Ben Clauberg as Vice President BD of the EU

AGC Biologics' CEO Patricio Massera steps down after leading company through growth and acquisitions; a search for a new CEO is underway, with Tadashi Murano appointed as interim CEO.

AGC Biologics completes Copenhagen campus expansion, doubling single-use mammalian bioreactor capacity to 150 batches/year; invested $200 million in the expansion, adding 19,000 m2 of space.

AGC Biologics and BioConnection form strategic partnership for seamless biopharmaceutical development and manufacturing; partnership offers full-service clinical-stage solution for drug substance and product development

Ask us about our Health Care Sector market view

Trending Chart

Interactive chart with headline count